TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

TLC Announces Positive End-of-Phase II Meeting with FDA for TLC599 in Knee Osteoarthritis SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 15, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...

Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through  Weeks 12, 16, 20, and 24 TLC599 was well-tolerated with no...